The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down
The app for the smartwatch includes secure encrypted messaging.
Time Inc., according to AdAge, has begun selling print ads for its magazines on exchanges.
A look at the content that grabbed most reader interest over the past year.
Haymarket Media launched the site PsychiatryAdvisor.com today.
Researchers are increasingly using social media to recruit patients, albeit oftentimes in an arms-length manner.
Guidance on promoting products in 140 characters and correcting misinformation serves as a guarded green light, says one observer.
Texting HCPs may be speedy, but a study finds some built-in risks.
The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.
The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."
Praised for helping navigate the shift by advertisers into digital, media vet Kim Kadlec is leaving pharma for a new role at AOL.
Express Scripts notes that these prescriptions may not, in fact, be for ADHD.
The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will flow toward reprints.
A month after UBM Canon closed the B2B magazine, marketing firm Outcomes LLC announced its return to twice-a-year publication.
The agency says outlets need to rethink running ads that make false claims.
Our year-end list captures the 10 that sparked heaviest interest.
The move to digitize a series of books it co-created with Disney for kids with type 1 diabetes was spurred by a meeting with the online diabetes community.
Elsevier is taking a hard-line posture against several different universities, asking them to take down scholarly research.
The Heath, Labor and Welfare ministry says a publisher passed off advertorials as articles.
EHRs could be a vehicle for pharma to find its way into the physician's workflow. First, industry needs to learn how to leverage them appropriately.
American Medical News's 55-year publishing history ended September 2, although the website will be maintained through the end of the year.
A research team found that Big Pharma has pulled back on publications despite doubling or even quadrupling research and development budgets
The company has partnered with Univision on a dance competition that supports health and weight loss. The segment, called Ritmo Dieta, will run for 13 weeks on the variety program Sábado Gigante.
For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.
News on JAMA Ophthalmology, the New England Journal of Medicine, Elsevier and Oxford University Press
A study published in JAMA Internal Medicine shows that encouraging patients to read up on a topic beforehand could make office visits more productive
MedPage Today's new VP and global editorial director, Ivan Oransky, has a goal in mind: to make the resource even more top-of-mind among the medical community by broadening and deepening its content and engagement
Remedy Health is hoping a new design for its flagship portal can give it an edge over rivals WebMD and Everyday Health.
American Medical News' 55-year publishing run will come to a close this year, the AMA, its publisher, said today.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.